Logo
Published Expertise
2009
  1. Dingemanse J, Halabi A, van Giersbergen PL. Influence of liver cirrhosis on the pharmacokinetics, pharmacodynamics, and safety of tezosentan. J Clin Pharmacol 2009; 49(4):455-464.
  2. Erpenbeck VJ, Fischer I, Wiese K, Schaumann F, Schmiedl A, Nassenstein C, Krug N, Hohlfeld JM. Therapeutic surfactants modulate the viability of eosinophils and induce inflammatory mediator release Int Arch Allergy Immunol 2009; Epub 2009 Mar 17.
  3. Feuring M, Ruf A, Schultz A, Wehling M. Blood group-dependent inhibition of platelet function by eptifibatide and abciximab. Submitted 2009.
  4. Feuring M, Wehling M, Schultz A. Circadian variation of platelet function measured with the PFA-100®. Platelets in press 2009.
  5. Lubenau H, Bias P, Maly AK, Siegler KE, Mehltretter K. Pharmacokinetic and pharmacodynamic profile of new biosimilar filgrastim XM02 equivalent to marketed filgrastim Neupogen: single-blind, randomized, crossover trial. BioDrugs 2009; 23(1):43-51.
  6. Leroux-Roels I, De Decker M, Meyer I, Seiberling M, Weber F, Leroux-Roels G. Reactogenicity of repeated seasonal influenza vaccine delivered by intradermal microinjection: results from a randomized controlled open label trial in adults. Presented at the 3rd Influenza Vaccines for the world 27-30 April 2009 Cannes, France
  7. Tebbe U, Bramlage P, Graf A, Lechleitner P, Bode C, Riess FC, Clemens N, Al-Rawi Y, Konstantinides S, Goldhaber SZ. Desmoteplase in acute massive pulmonary thromboembolism. Thromb Haemost. 2009 Mar; 101(3):557-62.

2008
  1. Leroux-Roels I, De Decker M, Meyer I, Seiberling M, Weber F, Leroux-Roels G. Reactogenicity of repeated seasonal influenza vaccine delivered by intradermal microinjection: results from a randomized controlled open label trial in adults. 8th Canadian Immunization Conference, November 30-Dezember 3, 2008
  2. Baumann S. Sublingual immunotherapy (SLIT) adjuvanted with monophosphoryl lipid A (MPL®): preliminary safety, efficacy and immunogenicity results. The journal of allergy and clinical immunology, 2008 Oct. 08-1059.
  3. Hohlfeld JM, Schoenfeld K, Lavae-Mokhtari M, Schaumann F, Mueller M, Bredenbroeker D, Krug N, Hermann R. Roflumilast attenuates pulmonary inflammation upon segmental endotoxin challenge in healthy subjects: a randomized placebo-controlled trial Pulm Pharmacol Ther. 2008 Aug;21 Epub 2008 Feb 21
  4. Schaumann F, Müller M, Braun A, Luettig B, Peden DB, Hohlfeld JM, Krug N. Endotoxin augments myeloid dendritic cell influx into the airways in patients with allergic asthma Am J Respir Crit Care Med. 2008 Jun 15;.Epub 2008 Apr 3. PubMed PMID: 18388357
  5. Fauteck JD, Ackermann G, Birkel M, Breuer M, Moor AC, Ebeling A, Ortland C. Fluorescence characteristics and pharmacokinetic properties of a novel self-adhesive 5-ALA patch for photodynamic therapy of actinic keratoses. Arch Dermatol Res. 2008 Feb; 300(2):53-60. Epub 2007 Oct 25.
  6. Rabe KF, Timmer W, Sagkriotis A, Viel K. Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD. Chest 2008; 134(2):255-262.
  7. Stass H, Kubitza D, Aydeniz B, Wallwiener D, Halabi A, Gleiter C. Penetration and accumulation of moxifloxacin in uterine tissue. Int J Gynaecol Obstet 2008; 102(2):132-136.
  8. Timmer W. Anforderungen an Einrichtungen zur Durchführung von Erstanwendungen (Demands on clinical units dedicated to the conduct of first-to-human trials). Lecture at the 10th Annual Congress of Clinical Pharmacology (VkliPha 2008), November 6-8, 2008, Berlin.
  9. Timmer W. Cardiac Safety – Dr Wolfgang Timmer of CRS examines the conduct of thorough QTc trials in practice from a Phase I CRO's perspective. European Pharmaceutical Contractor 2008; (Summer 08).
  10. Timmer W. Minimising risk by optimising clinical trial design and performance. Lecture and workshop at the annual meeting of the Arbeitsgemeinschaft für angewandte Humanpharmakologie [Association for Applied Human Pharmacology] (AGAH e.V.), April 17-19, 2008, Weimar.

2007
  1. De Bruijn I,  Meyer I, Gereza L,  Nautaa J,  Giezemana K, Palachea B 2007. Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly, Vaccine, Volume 26, Issue 1, 21 December 2007, Pages 119-127.
  2. Brand P, Meyer T, Weuthen T, Timmer W, Berkel E, Wallenstein G, Scheuch G. Lung deposition of radiolabeled tiotropium in healthy subjects and patients with chronic obstructive pulmonary disease. J Clin Pharmacol. 2007 Oct; 47(10):1335-41. Epub 2007 Jul 11.
  3. Goss PE, Hadji P, Subar M, Abreu P, Thomsen T, Banke-Bochita J. Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women. Breast Cancer Res 2007; 9(4):R52.
  4. Pfaar O, Fischer von Weikersthal-Drachenberg KJ, Amersdorffer J, Baumann-Noss S, Woroniecki SR, Klimek L. Sublingual immunotherapy adjuvanted with monophosphoryl lipid A: preliminary efficacy and immunogenicity results. Allergy 2007; s83.
  5. Roell A, Schueller P, Schultz A, Losel R, Wehling M, Christ M, Feuring M. Effect of oral contraceptives and ovarian cycle on platelet function. Platelets 2007; 18(2):165-70.
  6. Schnabel PG, Bagchus W, Lass H, Thomsen T, Geurts TB. The effect of food composition on serum testosterone levels after oral administration of Andriol Testocaps. Clin Endocrinol (Oxf) 2007; 66(4):579-585.
  7. Schmitt-Hoffman A, Roos B, Brown T, Meyer I., Alitretinoin (BAL4079; 9-cis retinoic acid): Pharmacokinetics after single and repeated oral dosing of 20 and 40mg in healthy volunteers. 16th Congress of the European Academy of Dermatology and Venereology (EADV) 2007
  8. Schmitt-Hoffman A, Meyer I, Roos B, Brown T, Maares, J. Alitretinoin (BAL4079; 9-cis retinoic acid): Pharmacokinetics after single and repeated oral dosing of 5, 10 and 20mg in healthy volunteers. Schmitt-Hoffman A, Roos B, Brown T, Maares J. 16th Congress of the European Academy of Dermatology and Venereology (EADV) 2007.

2006
  1. Jakobs R, Hartmann D, Kudis V, Eickhoff A, Schilling D, Weickert U, Siegler KE, Riemann JF. Risk factors for symptomatic stone recurrence after transpapillary laser lithotripsy for difficult bile duct stones using a laser with a stone recognition system. Eur J Gastroenterol Hepatol. 2006 May; 18(5):469-73.
  2. Mikus G, Schowel V, Drzewinska M, Rengelshausen J, Ding R, Riedel KD, Burhenne J, Weiss J, Thomsen T, Haefeli WE. Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir. Clin Pharmacol Ther 2006; 80(2):126-135.
  3. Sidharta PN, Wagner FD, Bohnemeier H, Jungnik A, Halabi A, Krähenbühl S, Chadha-Boreham H, Dingemanse J. Pharmacodynamics and pharmacokinetics of the urotensin II receptor antagonist palosuran in macroalbuminuric, diabetic patients. Clin Pharmacol Ther. 2006 Sep; 80(3):246-56.
  4. Timmer W. Klinische Arzneimittelentwicklung in der Industrie für Kinder unter Berücksichtigung von ICH-E11 [Clinical development of new drugs by the pharmaceutical industry in consideration of ICH-E11]. Lecture at the pediatric training course of the Koordinierungszentrum für Klinische Studien (KKS), May 30, 2006, University of Mainz.
  5. van Giersbergen PL, Halabi A, Dingemanse J. Pharmacokinetic interaction between bosentan and the oral contraceptives norethisterone and ethinyl estradiol. Int J Clin Pharmacol Ther 2006; 44(3):113-118.
  6. Vollmar J, Arndtz N, Eckl KM, Thomsen T, Petzold B, Mateo L, Schlereth B, Handley A, King L, Hülsemann V, Tzatzaris M, Merkl K, Wulff N, Chaplin P. Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine. Vaccine. 2006 Mar 15; 24(12):2065-70. Epub 2005 Nov 28.
  7. Wehling M, Schultz A, Losel R. Nongenomic actions of estrogens: Exciting opportunities for pharmacology. Maturitas 2006; 54: 321-26.
  8. Wehling M, Schultz A, Lösel R. To be or not to be (a receptor). Steroids 2006; 72(2):107-10.

2005
  1. Brockmoller J, Thomsen T, Wittstock M, Coupez R, Lochs H, Roots I. Pharmacokinetics of levetiracetam in patients with moderate to severe liver cirrhosis (Child-Pugh classes A, B, and C): characterization by dynamic liver function tests. Clin Pharmacol Ther 2005; 77(6):529-541.
  2. Dogterom P, van den Heuvel MW, Thomsen T. Absence of pharmacokinetic interactions of the combined contraceptive vaginal ring NuvaRing with oral amoxicillin or doxycycline in two randomised trials. Clin Pharmacokinet 2005; 44(4):429-438.
  3. Feuring M, Harenberg J, Peiter A, Ganschow A, Ruf A, Losel R, Wehling M, Schultz A. Impact of ABO blood groups on tirofiban mediated inhibition of platelet function. Platelets 2005; 16:430-4.
  4. Feuring M, Schultz A, Losel R, Wehling M. Monitoring Acetylsalicylic Acid Effects with the Platelet Function Analyzer PFA-100. Semin Thromb Hemost 2005; 31:411-5.
  5. Grossmann M, Baumann-Noss S, Voisin D, Parisi S. Evaluation of pharmacokinetic (PK) interaction between palonosetron (PALO) and dexamethason (DEX): A randomized, crossover study in healthy subjects. ECCO 2005. Abstract.
  6. Pietruck F, Kiel G, Birkel M, Stahlheber-Dilg B, Philipp T. Evaluation of the effect of candesartan cilexetil on the steady-state pharmacokinetics of tacrolimus in renal transplant patients. Biopharm Drug Dispos 2005; 26(4):135-141.
  7. Rengelshausen J, Banfield M, Riedel KD, Burhenne J, Weiss J, Thomsen T, Walter-Sack I, Haefeli WE, Mikus G. Opposite effects of short-term and long-term St John's wort intake on voriconazole pharmacokinetics. Clin Pharmacol Ther. 2005 Jul; 78(1):25-33. Comment in: Clin Pharmacol Ther. 2005 Jul; 78(1):19-24.
  8. Schmidt BM, Horisberger K, Feuring M, Schultz A, Wehling M. Aldosterone blunts human baroreflex sensitivity by a nongenomic mechanism. Exp Clin Endocrinol Diabetes 2005; 113: 252-6.
  9. Schultz A. Therapeutischer Fortschritt beim akuten Koronarsyndrom durch Statine? Perfusion 2005; 18: 285-7.
  10. Senges-Becker JC, Klostermann M, Becker R, Bauer A, Siegler KE, Katus HA, Schoels W. What is the "optimal" follow-up schedule for ICD patients? Europace. 2005 Jul; 7(4):319-26.
  11. Stahlberg HJ, Beier H, Baumann-Noss S, Birkel M. Bioequivalence of a new clarithromycin 250 mg dst (dose sipping technology) granule formulation (clarosip®) compared to an equimolar reference suspension formulation (zeclar®). Abstract. 2005.
    n (zeclar®). Abstract. 2005.
2004
  1. Theiß U. Acne Vulgaris – ein verbreitetes Problem. Zunehmender Stellenwert der Therapiebegleitenden Hautpflege. Haut, Band XV, 214-215, September 2004
  2. Schley P, Sause A, Shin DI, Klein RM, Müller M, Ghouzi A, Schemeitat K, Burkhard-Meier C, Gülker H, Horlitz M. Curative therapy in symptomatic atrial ectopy. Internist (Berl). 2004 Nov;45(11):1299-304
  3. Schaumann F, Borm PJ, Herbrich A, Knoch J, Pitz M, Schins RP, Luettig B, Hohlfeld JM, Heinrich J, Krug N. Metal-rich ambient particles (particulate matter 2.5) cause airway inflammation in healthy subjects. Am J Respir Crit Care Med. 2004 Oct 15; Epub 2004 Jun 30.
  4. Agrawal NG, Matthews CZ, Mazenko RS, Woolf EJ, Porras AG, Chen X, Miller JL, Michiels N, Wehling M, Schultz A, Gottlieb AB, Kraft WK, Greenberg HE, Waldman SA, Curtis SP, Gottesdiener KM. The effects of modifying in vivo cytochrome P450 3A (CYP3A) activity on etoricoxib pharmacokinetics and of etoricoxib administration on CYP3A activity. J Clin Pharmacol 2004; 44: 1125-31.
  5. Bagchus WM, Houwing NS, Schnabel P, Lass H, Thomsen T. Effect of meal composition on serum testosterone level after oral administration Andriol® Testocaps®. Prague - Czech Republic: The 4th world congress on the aging male; February 26-29, 2004.
  6. Burkhardt U, Zahn R, Hoffler U, Siegler KE, Frilling B, Weber M, Gottwik M, Wehr M, Seidel F, Rosocha S, Tebbe U, Senges J. Antibody levels against Chlamydia pneumoniae and outcome of roxithromycin therapy in patients with acute myocardial infarction. Results from a sub-study of the randomised Antibiotic Therapy in Acute Myocardial Infarction (ANTIBIO) trial. Z Kardiol. 2004 Sep; 93(9):671-8.
  7. Dingemanse J, Halabi A, Hoever P, Chadha-Boreham H, van Giersbergen PL. Clinical pharmacology of tezosentan, a dual endothelin receptor antagonist, in patients with liver cirrhosis. 105th Am.Soc. Clin. Pharmacol. Ther. Meeting, Miami Beach, FL, 2204, March 24-27. Clin Pharmacol Ther 2004; 75: P31.
  8. Teddy Kosoglou, Paul Statkevich, Ingo Meyer, David L Cutler, Bernhard Musiol, Bo Yang, Yali Zhu, Stephen E Maxwell, Enrico P Veltri. Effects of ezetimibe on the pharmacodynamics and pharmacokinetics of lovastatin. Current Medical Research and Opinion 06/2004; 20(6):955-65.
  9. Dogterom P, Heuvel van den MM, Thomsen T, Verhoeven C. NuvaRing does not interact with oral antibiotics. Edinburgh - Scottland: 8th Congress of the European Society of Contraception; 2004.
  10. Dogterom P, van den Heuvel MM, Thomsen T. The contraceptive vaginal ring, NuvaRing®, shows no interaction with oral antibiotics. 04 Mar 24; Miami - Florida: ASCPT 2004 Annual Meeting, March 24-27, 2004.
  11. Doser S, Marz W, Reinecke MF, Ringleb P, Schultz A, Schwandt P, Becker HJ, Bonner G, Buerke M, Diener HC, Gohlke H, Keil U, Ringelstein EB, Steinmetz A, Gladisch R, Wehling M [Recommendations for statin therapy in the elderly]. Internist (Berl) 2004; 45: 1053-62.
  12. Grossmann M, Ebert U, Baumann- Noss S, Birkel M, Renner J, Luecker PW. An approach to characterize pharmacokinetic – pharmacodynamic bioequivalence of propofol. ASCPT 2004, Annual Meeting. Abstract.
  13. Junge W, Wilke B, Halabi A, Klein G. Determination of reference intervals for serum creatinine, creatinine excretion and creatinine clearance with an enzymatic and a modified Jaffe method. Clin Chim Acta 2004; 344(1-2):137-148.
  14. Losel R, Schultz A, Boldyreff B, Wehling M. Rapid effects of aldosterone on vascular cells: clinical implications. Steroids 2004; 69:575-8.
  15. Losel R, Schultz A, Wehling M. A quick glance at rapid aldosterone action. Mol Cell Endocrinol 2004; 217: 137-41.
  16. Schöwel V, Drzewinska M, Burhenne J, Riedel KD, Thomsen T, Weiss J, Rengelshausen J, Haefeli WE, Mikus G. CYP2C19 genotype releated, potent interaction between voriconazole and ritonavir. Stuttgart - Deutschland: 6. Jahreskongress für Klinische Pharmakologie; 2004.
  17. Subar M, Goss PE, Thomsen T, Banke-Bochita J. Effects of steroidal and nonsteroidal aromatase inhibitors (AIs) on markers of bone turnover and lipid metabolism in healthy volunteers. Journal of Clinical Oncology; 2004.
  18. Tillmann HC, Stuck BA, Feuring M, Rossol-Haseroth K, Tran BM, Losel R, Schmidt BM, Hormann K, Wehling M, Schultz A. Delayed genomic and acute nongenomic action of glucocorticosteroids in seasonal allergic rhinitis. Eur J Clin Invest 2004; 34: 67-73.
  19. Tran-Mi B, Storch H, Seidel K, Schulzki T, Haubelt H, Anders C, Nagel D, Siegler KE, Vogt A, Seiler D, Hellstern P. The impact of different intensities of regular donor plasmapheresis on humoral and cellular immunity, red cell and iron metabolism, and cardiovascular risk markers. Vox Sang. 2004 Apr; 86(3):189-97.
  20. Zeymer U, Zahn R, Siegler KE, Senges J. Eptifibatide in patients with percutaneous coronary intervention in clinical practice. Results of a prospective registry. Herz. 2004 Nov; 29(7):651-5.
2003

  1.  
2002
  1. B.Ramjattan, D. Callaghan U. Theiß. Efficacy and Tolerability of a “Suprabioavailable” Formulation of Fenofibrate in Patients with Dyslipidemia : A Pooled Analysis of Two Open-Label Trials.  Clinical Therapeutics, Vol. 24, No 7, Excerpta Medica 2002
  2. Feuring M, Bertsch T, Tran BM, Rossol-Haseroth K, Losel R, Tillmann HC, Schultz A, Weigel M, Wehling M. Seminal plasma hormone concentration after oral application of progesterone. Int J Clin Pharmacol 2002; Ther 40: 47-52.
  3. Feuring M, Christ M, Roell A, Schueller P, Losel R, Dempfle CE, Schultz A, Wehling M. Alterations in platelet function during the ovarian cycle. Blood Coagul Fibrinolysis 2002; 13: 443-7.
  4.  Feuring M, Bertsch T, Tran BM, Rossol-Haseroth K, Losel R, Tillmann HC, Schultz A, Weigel M, Wehling M. Seminal plasma hormone concentration after oral application of progesterone. Int J Clin Pharmacol 2002; Ther 40: 47-52.
  5. Feuring M, Christ M, Roell A, Schueller P, Losel R, Dempfle CE, Schultz A, Wehling M. Alterations in platelet function during the ovarian cycle. Blood Coagul Fibrinolysis 2002; 13: 443-7.
  6. Frilling B, Zahn R, Fraiture B, Mark B, Donges K, Becker T, Siegler KE, Seidl K, Rustige J, Senges J. Comparison of efficacy and complication rates after percutaneous coronary interventions in patients with and without renal insufficiency treated with abciximab. Am J Cardiol. 2002 Feb 15; 89(4):450-2.
  7. Goss PE, Thomsen T, Banke-Bochita J, Lowery C, D'Angelo P, Asnis A. A randomized, placebo-controlled, explorative study to investigate the effect of low estrogen plasma levels on markers of bone turnover in healthy pos. 02 Dec 11; San Antonio - Texas: 25th Annual San Antonio Breast Cancer Symposium, December 11-14, 2002.
  8. Senges JC, Becker R, Schreiner KD, Bauer A, Weretka S, Siegler K, Kuebler W, Schoels W. Variability of Holter electrocardiographic findings in patients fulfilling the noninvasive MADIT criteria. Multicenter Automatic Defibrillator Implantation Trial. Pacing Clin Electrophysiol. 2002 Feb; 25(2):183-90.
  9. Stass H, Kubitza D, Halabi A, Delesen H. Pharmacokinetics of moxifloxacin, a novel 8-methoxy-quinolone, in patients with renal dysfunction. Br J Clin Pharmacol 2002; 53(3):232-237.
  10. Thomsen T, Eckl KM. Praktische, klinisch-pharmakologische Tätigkeit am Probanden und Patienten (Phase I). In: Herrlinger C, Cawello W, editors. Kompendium der Klinischen Pharmakologie. Aachen: Shaker Verlag; 2002. 517-554.
  11. van Giersbergen PL, Halabi A, Dingemanse J. Single- and multiple-dose pharmacokinetics of bosentan and its interaction with ketoconazole. Br J Clin Pharmacol 2002 Jun; 53(6):589-595.
  12. Vanscheidt W, Jost V, Wolna P, Lücker PW, Müller A, Theurer C, Patz B, Grützner KI. Efficacy and safety of a Butcher's broom preparation (Ruscus aculeatus L. extract) compared to placebo in patients suffering from chronic venous insufficiency. Arzneimittelforschung 2002; 52(4):243-50.
  13. Kosoglou, T., Meyer, I., Veltri, P., Statkevich, P., Yang, B., Zhu, Y. Mellears, L., Maxwell, S., Patrik, J.Cutler, D., Vijay, B., Affrime, M., 2002. Pharmacodynamic interaction between the new selective cholesterol absorbtion inhibitor ezetimibe and simvastatin. Br J Clin Pharmacol 10/2002, 54, 309-319
2001
  1. Feuring M, Gutfleisch A, Ganschow A, Richter E, Eichler H, Dempfle CE, Tillmann HC, Schultz A, Wehling M. Impact of plasmapheresis on platelet hemostatic capacity in healthy voluntary blood donors detected by the platelet function analyzer PFA-100. Platelets 2001; 12: 236-40.
  2. Junge W, Wilke B, Halabi A, Klein G. Creatinine excretion and creatinine clearance: determination of reference intervals using a specific enymatic and a modified Jaffé method. July 29 – August 2, 2001. AACC/CSCC, Annual Meeting & Clin Lab Expo.
  3. Kienle E, Hillger H, Hübner R, Jost V. Prospektive, randomisierte Studie zur Wirksamkeit und Verträglichkeit des GnRH-Analogons Leuprorelinacetat als 1- und 3-Monats-Depot bei Patientinnen mit Uterus myomatosus. Geburtsh Frauenheilk 2001; 61: 784-787.
  4. Ullmann U, Lehnfeld R, Bliesath H, Birkel M, Gebbing H, Gräve M, Wolf H. Relative bioavailability of imipramine (Tofranil) coated tablets in healthy volunteers. Int J Clin Pharmacol Ther. 2001 Jun; 39(6):271-6.
  5. Kosoglou T, Meyer I, Musiol B, Anderson L, Reyderman L, Statkevich P, et al. Pharmacodynamic interaction between fluvastatin and ezetimibe has favorable clinical implications.  Presented at the 72nd European Atherosclerosis Congress, Glasgow, U.K.  May 2001.
  6. Kosoglou T, Meyer I, Musiol B, Anderson L, Reyderman L, Statkevich P, et al. Pharmacodynamic interaction between fluvastatin and ezetimibe has favorable clinical implications [abstract P171]. Atherosclerosis Suppl 2001;2(2):89.
2000
  1. Kosoglou T, Meyer I, Musiol B, Cutler DL, Yang B, Maxwell SE, Veltri EP, Affrime MB.  Coadministration of simvastatin and ezetimibe leads to significant reduction in LDL?cholesterol.  Presented at the 3rd International Congress on Coronary Artery Disease, Lyon, France, October 2000.
  2. Lücker PW, Jost V, Wolna P, Patz B, Theurer C. Efficacy and safety of butcher’s broom rhizoma extract (ruscus aculeatus l.) compared to placebo in patients suffering from chronic venous insufficiency. Abstract, 3rd International Congress on Phytomedicine, Munich, Germany, 11-13 October 2000.
  3. M Bindschedler, G Lefèvre, F Ezzet, N Schaeffer, I Meyer, M S Thomsen. Cardiac effects of co-artemether (artemether/lumefantrine) and mefloquine given alone or in combination to healthy volunteers. European Journal of Clinical Pharmacology 09/2000; 56(5):375-81
  4. Kosoglou T, Meyer I, Musiol B, Mellars L, Statkevich P, Miller MF, Soni PP, Affrime MB.  Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin.  Presented at the XIIth International Symposium on Atherosclerosis meeting, Stockholm, Sweden, June 2000.
  5. Lefèvre, G., Bindschedler, M., Ezzet, F., Schäfer, N., Meyer, I., Thomson, M.S., 2000. Pharmakokinetic interaction trial between co-artemether and mefloquine. European Journal of Pharmaceutical Sciences 10 (2000) 141-151.
  6. Popken G, Schultze-Seemann W, Seiler KU, Birkel M, Wetterauer U. Intravesical administration of 5-aminolevulinic acid (5-ALA). Safety and pharmacokinetics of 5-ALA and its metabolite protoporphyrin IX. Eur J Clin Pharmacol 2000; 56(3):241-246.
  7. Kosoglou T, Meyer I, Musiol B, Mellars L, Statkevich P, Miller MF, Soni PP, Affrime MB.  Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin. Atherosclerosis 2000;151 (Abstr. Suppl.):133.
  8. Kosoglou T, Meyer I, Musiol B, Cutler DL, Yang B, Maxwell SE, Veltri EP, Affrime MB.  Coadministration of simvastatin and ezetimibe leads to significant reduction in LDL?cholesterol.  International Congress on Coronary Artery Disease Abstract Book 2000;3:71 [abstract 275].
  9. Kosoglou T, Meyer I, Cutler DL, Musiol B, Yang B, Zhu Y, Maxwell SE, Affrime MB, Veltri EP.  Pharmacodynamic interaction between the selective cholesterol absorption inhibitor ezetimibe and lovastatin.  International Congress on Coronary Artery Disease Abstract Book 2000;3:101 [abstract 390].
  10. Knichwitz G, Brüssel T, Reinhold P, Schaumann F, Richter KD, Van Aken H. f regional intestinal ischemia can be detected with carbon dioxide tension measurement inside the peritoneal cavity AnesthAnalg. 2000 Nov; 91(5):1182-7
  11. Degen, J., Seiberling, M.,  Meyer, I., Thomann, P., Schürholz, T., 2000. Influence of a nasal spray consisting of a standardized  composition of Citrus Limon (Succus)  and an aqueous extract from Cydonia Oblonga (Fructus) on the intranasal mucociliary clearance. Arzneimittelforschung Drug Research 1/2000
FooterEnd